Wartość Gotówka na akcję organizacji Panbela Therapeutics Inc. to 0.43
Gotówka na akcję to gotówka firmy podzielona przez akcje spółki.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.